Cafepharma Today

May 13 2025 - GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
Elizabeth Holmes’s partner reportedly raises millions for blood-testing startup
Bluebird bio warns of potential bankruptcy after another buyout delay
HIV market expected to reach $32.1bn by 2033 in 7MM
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

How Big Will Johnson & Johnson’s Legal Bill Grow?
Wall St. Cheat Sheet
Thursday, April 18, 2013 - 7:58am
tags:
JNJ
Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
Seeking Alpha
Wednesday, April 17, 2013 - 4:40pm
tags:
diabetes, Eli Lilly, dulaglutide, Novo Nordisk, Sanofi
3 Things You Need to Watch at Johnson & Johnson
Motley Fool
Wednesday, April 17, 2013 - 4:38pm
tags:
JNJ, devices, Invokana, Stelara
3 Potential Game Changers for America's No. 1 Killer
Motley Fool
Wednesday, April 17, 2013 - 4:36pm
tags:
heart disease, Novartis, serelaxin, Pfizer, Inspra, Regeneron, Sanofi, PCSK9 inhibitors
Glaxo-Theravance Lung Drug Gains Backing of FDA Advisers
Bloomberg
Wednesday, April 17, 2013 - 4:34pm
tags:
GSK, Breo Ellipta, FDA, COPD, Theravance
Top 10 pharma companies by employees
Fierce Pharma
Wednesday, April 17, 2013 - 11:31am
tags:
Novartis, JNJ, Sanofi, GSK, Pfizer, Abbott Laboratories, Merck, Roche, Bayer, AstraZeneca
Illumina: Thermo Fisher-Life Deal Unlikely To Threaten Its Market-Leading Position
Seeking Alpha
Wednesday, April 17, 2013 - 11:15am
tags:
Illumina, Thermo Fisher, M&A, Life Technologies, Pacific Biosciences
Mixed Messages on COPD Drug, FDA Review Finds
Med Page Today
Wednesday, April 17, 2013 - 11:13am
tags:
FDA, COPD, Breo Ellipta, GSK, Theravance
Did Someone Say Kickbacks? Amgen Pays $29M Over Aranesp Marketing
Pharmalot
Wednesday, April 17, 2013 - 11:08am
tags:
Amgen, Aranesp, kickbacks
3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak
Seeking Alpha
Wednesday, April 17, 2013 - 11:07am
tags:
Flu, H7N9, Sanofi, Novavax, Biocryst, Gilead, GSK, Merck, Roche, Inovio
Hikma to Keep Injectable-Drug Unit After Completing Review
Bloomberg
Wednesday, April 17, 2013 - 11:04am
tags:
injectables, Hikma, Amgen, Novartis
Vivus Gets Restrictions Loosened; Will Be Available in Retail Pharmacies Later This Year
Seeking Alpha
Wednesday, April 17, 2013 - 11:03am
tags:
Vivus, Qsymia, Orexigen, obesity, Arena Pharmaceuticals
Investing In The Stem Cell Sector: An Overview
Seeking Alpha
Wednesday, April 17, 2013 - 11:01am
tags:
stem cells, Advanced Cell Technology, Aastrom Biosciences, BrainStorm Cell Therapeutics, Cytomedix, Neuralstem, Cytori, Fibrocell Science, International Stem Cell Corp, NeoStem, InVivo, Osiris, Pleuristem, RegenoCell, StemCells, Athersys
MannKind's Mysterious Lung-Safety Study Is Open But Shhh...Don't Talk About It
TheStreet.com
Wednesday, April 17, 2013 - 10:56am
tags:
MannKind, inhaled insulin, Afrezza, diabetes
Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis
Yahoo
Wednesday, April 17, 2013 - 10:55am
tags:
ALS, FDA, Neuralstem, Lou Gehrig's disease, NSI-566
Blood Clots Are Big Market For Biotech Medicines Co.
Investors.com
Wednesday, April 17, 2013 - 10:54am
tags:
blood clots, Medicines Company, Angiomax, Cleviprex, Recothrom, Argatroban
Lilly to acquire Alzheimer's imaging agents from Siemens
Reuters
Wednesday, April 17, 2013 - 10:52am
tags:
Alzheimer's disease, Siemenfs, imaging agents
Amarantus LymPro Could Be A Game-Changer For Alzheimer's Diagnosis
Seeking Alpha
Wednesday, April 17, 2013 - 10:51am
tags:
LymPro, Amarantus BioSciences, Alzheimer's disease, Pfizer, Forest Labs, Eli Lilly
Array's Up-Coming Value Enhancing Catalysts
Seeking Alpha
Wednesday, April 17, 2013 - 10:50am
tags:
Array Biopharma, Amgen, Novartis, AstraZeneca, selumetinib, MEK162, melanoma, non-small cell lung cancer
Abbott’s Profit Rose on Nutritional Product Sales
Bloomberg
Wednesday, April 17, 2013 - 10:48am
tags:
earnings, Abbott Laboratories

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline
Treating Orthopox Viruses - With What?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.